How to use statins in patients with chronic liver disease

被引：33
作者：
Russo, MW [1 ]
Jacobson, IM [1 ]
机构：
[1] Weill Cornell Med Coll, Div Gastroenterol & Hepatol, Ctr Study Hepatitis C, New York, NY USA
来源：
CLEVELAND CLINIC JOURNAL OF MEDICINE | 2004年 / 71卷 / 01期
关键词：
D O I：
10.3949/ccjm.71.1.58
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Clinicians may be concerned about prescribing statins to patients with chronic liver disease, but there is little evidence to suggest that drug-induced liver injury from statins is increased in these patients. Thus, we should prescribe statins for the same indications in patients with chronic liver disease as in patients without, but with closer monitoring. However, patients with acute liver disease (acute viral hepatitis, alcoholic hepatitis) should not take statins until they have recovered.
引用
收藏
页码：58 / 62
页数：5
相关论文
共 17 条
  • [1] Rosuvastatin
    Carswell, CI
    Plosker, GL
    Jarvis, B
    [J]. DRUGS, 2002, 62 (14) : 2075 - 2085
  • [2] Nonalcoholic fatty liver disease
    Clark, JM
    Brancati, FL
    Diehl, AM
    [J]. GASTROENTEROLOGY, 2002, 122 (06) : 1649 - 1657
  • [3] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
  • [4] Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS
    Downs, JR
    Clearfield, M
    Weis, S
    Whitney, E
    Shapiro, DR
    Beere, PA
    Langendorfer, A
    Stein, EA
    Kruyer, W
    Gotto, AM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20): : 1615 - 1622
  • [5] Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care - The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)
    Furberg, CD
    Wright, JT
    Davis, BR
    Cutler, JA
    Alderman, M
    Black, H
    Cushman, W
    Grimm, R
    Haywood, LJ
    Leenen, F
    Oparil, S
    Probstfield, J
    Whelton, P
    Nwachuku, C
    Gordon, D
    Proschan, M
    Einhorn, P
    Ford, CE
    Piller, LB
    Dunn, JK
    Goff, D
    Pressel, S
    Bettencourt, J
    deLeon, B
    Simpson, LM
    Blanton, J
    Geraci, T
    Walsh, SM
    Nelson, C
    Rahman, M
    Juratovac, A
    Pospisil, R
    Carroll, L
    Sullivan, S
    Russo, J
    Barone, G
    Christian, R
    Feldman, S
    Lucente, T
    Calhoun, D
    Jenkins, K
    McDowell, P
    Johnson, J
    Kingry, C
    Alzate, J
    Margolis, KL
    Holland-Klemme, LA
    Jaeger, B
    Williamson, J
    Louis, G
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (23): : 2998 - 3007
  • [6] Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia
    Hunninghake, D
    Insull, W
    Knopp, R
    Davidson, M
    Lohrbauer, L
    Jones, P
    Kafonek, S
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (06) : 635 - 639
  • [7] Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvalstaltin, and pravastatin across doses (STELLAR* trial)
    Jones, PH
    Davidson, MH
    Stein, EA
    Bays, HE
    McKenney, JM
    Miller, E
    Cain, VA
    Blasetto, JW
    STELLAR Study Grp
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (02) : 152 - 160
  • [8] *MED EC COMP, 2000, PHYS DESK REF
  • [9] Liver fibrosis attributed to lipid lowering medications: two cases
    Punthakee, Z
    Scully, LJ
    Guindi, MM
    Ooi, TC
    [J]. JOURNAL OF INTERNAL MEDICINE, 2001, 250 (03) : 249 - 254
  • [10] The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
    Sacks, FM
    Pfeffer, MA
    Moye, LA
    Rouleau, JL
    Rutherford, JD
    Cole, TG
    Brown, L
    Warnica, JW
    Arnold, JMO
    Wun, CC
    Davis, BR
    Braunwald, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) : 1001 - 1009
12